|
Synonyms: AD-85481 | ALN-85481 | ALN-AGT01
Compound class:
Nucleic acid
Comment: Zilebesiran (ALN-AGT01) is a small interfering RNA (siRNA) that is designed to target angiotensinogen (AGT) mRNA in the liver as a mechanism to treat hypertension [1-2]. The molecule is N-acetylgalactosamine (GalNAc) modified to enhance hepatic delivery via binding to liver-expressed asialoglycoprotein receptors (ASGRs). In the nucleotide sequences provided here (from the INN record) the GalNAc sugar is attached at the R1 position. The nucleotides are chemically modified (2'-O-methylnucleotides/2'-MOE and 2'-deoxy-2'-fluoronucleotide/2'-F monomers), with a mixed phosphorothioate/phosphate backbone.
|
Classification ![]() |
|
| Compound class | Nucleic acid |
| Compound subclass | siRNA |
| Target | angiotensinogen (AGT) mRNA |
International Nonproprietary Names ![]() |
|
| INN number | INN |
| 11531 | zilebesiran |
Synonyms ![]() |
| AD-85481 | ALN-85481 | ALN-AGT01 |
Database Links ![]() |
|
| CAS Registry No. | 2380166-33-4 (source: WHO INN record) |
| DrugBank Ligand | DB18929 |
| Search PubMed clinical trials | zilebesiran |
| Search PubMed titles | zilebesiran |
| Search PubMed titles/abstracts | zilebesiran |